Skip to content

    BASF India

    BASFNeutral
    Chemicals·21 Nov 2025
    Management Summary

    BASF India faced a challenging Q2 FY26 characterized by significant pricing pressure due to global overcapacity, particularly from China, which offset modest volume gains. While the Nutrition & Care segment showed exceptional resilience with both volume and price growth, the core Materials and Agricultural segments struggled with lower realizations and weather-related disruptions. The company is aggressively pursuing a 'differentiated steering' strategy, including the demerger of its Ag-solutions business and a partial divestment of its coatings business to Carlyle.

    Highlights

    8

    • Total sales for H1 FY26 stood at ₹7,900 crores, a 4% decline YoY.

    • Q2 FY26 Revenue was ₹4,000 crores, down 5% YoY, driven by a 7% drop in price realization despite a 2% volume growth.

    • PBT before exceptional items for Q2 fell by 16% YoY, while H1 PBT saw a sharper decline of 27% YoY.

    • Nutrition & Care emerged as the 'star' segment with H1 sales of ₹1,700 crores, achieving 8% volume growth and 4% price increases.

    • Agricultural Solutions segment H1 sales declined by approximately ₹80 crores due to an untimely and excessive monsoon.

    • Net Working Capital increased to ₹2,500 crores from ₹1,500 crores YoY, primarily due to a ₹750 crore reduction in accounts payable.

    • The demerger of the Agricultural Solutions business is on track for completion in FY27 with a 1:1 share entitlement ratio.

    • Management announced an 80% capacity expansion in the engineering plastics compounding line at the Thane site.

    Concerns

    1

    • China Industrial Overcapacity

    What Changed2

    vs Q4 FY26

    Risks discussed7 → 3 (-4)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹4,000 Cr-5%YoY
    2. 02PBT before Exceptional Items—-16%YoY
    3. 03H1 EPS₹56.5
    4. 04Volume Growth2%+2%YoY
    5. 05Price Realization-7%-7.0%YoY

    Segment breakdown

    Materials
    27% Revenue Share₹-400 Cr H1 Revenue Impact
    Nutrition & Care
    ₹1,700 Cr H1 Revenue8% Volume Growth4% Price Growth
    Industrial Solutions
    ₹1,400 Cr H1 Revenue5% EBIT Margin
    Agricultural Solutions
    17% Revenue Share₹-80 Cr H1 Revenue Impact
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Other
    Agricultural Solutions Demerger Completion
    FY27
    		High
    Other
    Coatings Business Transaction Closure
    Q2 CY2026
    		High
    Capacity
    Engineering Plastics Compounding Extrusion Line Capacity
    80% increase
    		High
    Capacity
    Cellesto New Facility Commissioning
    H2 2026
    		High
    Margin
    Industrial Solutions EBIT Margin
    >5%
    		Medium

    Risks & concerns

    5
    RiskSeverity

    China Industrial Overcapacity

    Management explicitly cited overcapacity in China as the primary driver for a 7% drop in price realizations. — Management acknowledged

    high

    Working Capital Strain

    Net working capital jumped by ₹1,000 crores YoY, largely because payables were cleared faster while receivables remained high. — Both acknowledged

    medium

    Raw Material Cost Volatility

    Higher input costs and unfavorable product mix impacted PBT by 16% in the quarter. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Promoter stake sale plans
    • Specific Capex figures for the Cellesto expansion

    Q&A highlights

    3

    “I think it would not be fair to say that we see an immediate sort of hockey stick type improvement... the overcapacity situation in China, especially with a geopolitical tariff... will continue to be a difficult element.”

    Confirms that the deflationary pressure from China is structural and unlikely to reverse in the near term, impacting realizations.

    asked by Rohit Nagraj

    2 min read5 chapters

    Detailed Narrative

    01

    Pricing Deflation Offsets Volume Gains

    BASF India reported a 2% volume growth in Q2 FY26, yet overall revenue declined by 5% YoY. This was primarily due to a sharp 7% reduction in price realizations across the board. Management attributed this deflationary environment to industrial overcapacity in China and geopolitical tensions, stating that they do not expect an immediate 'hockey stick' recovery in pricing.

    02

    Nutrition & Care: The Portfolio Outperformer

    The Nutrition & Care segment was described as the 'star' of the quarter, contributing ₹1,700 crores to H1 sales. It achieved a rare combination of 8% volume growth and 4% price increases. Profitability in the nutrition and health sub-unit nearly doubled from ₹14 crores to ₹27 crores, benefiting from strong demand in personal care and fragrances.

    03

    Strategic Demerger and Divestment

    The company is moving forward with its 'differentiated steering' strategy. The Agricultural Solutions business is being demerged into a new entity, BASF Agricultural Solutions India Limited, with a 1:1 share ratio and expected completion in FY27. Additionally, a binding agreement has been reached to carve out the coatings business into a standalone entity with Carlyle holding a 60% stake, expected to close by Q2 CY2026.

    04

    Working Capital and Cash Flow Pressure

    Cash flow from operations saw a significant decline of ₹900 crores. This was driven by a ₹1,000 crore increase in net working capital, which reached ₹2,500 crores. A major factor was the ₹750 crore reduction in accounts payable as the company cleared dues on time, coupled with slightly higher inventory levels in the Agricultural segment due to monsoon-related delays.

    05

    Capacity Expansion and Localization Strategy

    To reduce reliance on imports from Germany, BASF is investing in local capacity. The engineering plastics compounding line at Thane is being expanded by 80%. Furthermore, a new facility for Cellesto (polyurethane) is under construction and slated for commissioning in H2 2026, aimed at capturing growth in the Indian automotive sector, including EVs and 2-wheelers.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.